AAV hFIX (Regenxbio)

N/A

Report date: 2023/10/26 16:02:59

Base Information

Drug NameAAV hFIX (Regenxbio)
Drug Alias NameFIX gene therapyFactor IX gene therapyscAAV 2/8-LP1-hFIXco
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2/8 vector
Mechanisms of ActionBlood coagulation pathway activationCoagulation factor IX modulatorsFactor IX gene transference
TargetsCoagulation factor IX
Therapy Area/IndicationsHemophilia B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRegenxbio Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRegenxbio Inc
Active IndicationsN/A
Inactive IndicationsHemophilia B

Other Information

ATC CodeN/A
Related LinksN/A